New Grant Award for Discovery of Aptamers to Canine Oncology Biomarkers
Comparative oncology is the study of naturally-occurring cancer in animals to identify treatments that can be applied to humans. Many types of cancer, including several types that are identical to human cancer, are very common in dogs. Clinicians are learning that curing cancer in dogs can frequently result in effective cures for humans. Read more about canine cancer research. Base Pair Biotechnologies has recently been awarded an NIH SBIR Contract entitled, “Development and Validation of Non-Mouse Reagents to Enable Preclinical Development of Novel Therapeutics”. “It is increasingly understood that the canine model is a much higher fidelity representation for studying human cancer than smaller mammals. Using our patented ability to multiplex aptamer selection, Base Pair is in a unique position to rapidly discover affinity reagents to important canine cancer biomarkers. These new reagents should quickly prove useful in the study of cancer in dogs and, ultimately, translation of new therapeutics from preclinical trials to the treatment of human cancers.” – Dr. Bill Jackson, Founder and Chief Scientist, Base Pair Biotechnologies
New Base Pair Publication: Inhibition of Vitamin C Oxidation by DNA Aptamers
Base Pair has discovered an aptamer that inhibits the oxidation of vitamin C. The initial aptamer reduced vitamin C oxidation 2-fold to 4-fold under oxidizing conditions. Preliminary results suggest the potential for aptamers as stabilizers of key ingredients in beverages, nutritional supplements, and cosmetics. View Article PDF
DNA Aptamers or RNA Aptamers?
A growing number of researchers are turning to custom aptamer selection for detection of difficult targets, including small molecules and toxic compounds, and selective detection of highly similar compounds, but is it better to select for DNA aptamers or RNA Aptamers? Visit DNA Aptamers or RNA Aptamers? to learn more.
Bill Jackson Ph.D. discusses aptamers and aptamer selection, the differences between aptamers and antibodies, aptamer advantages, aptamer development at Base Pair, and data for a wide range of aptamer-based applications in research, diagnostics, and therapeutics.
Thank you to our recent Base Pair Biotechnologies Aptamer Survey winners from: Philadelphia, PA, USA San Diego, CA, USA Ontario, Canada
Bill Jackson Ph.D. and CSO at Base Pair Biotechnologies was interviewed for an article in International Innovation, Health Partnership, the leading global dissemination resource for the wider scientific, technology and research communities. The article entitled “Apt Aptamer Technology” on page 100 of the August 2013 issue explores how aptamers are proving an effective alternative to conventional immunization and information on Base Pair’s patented approach to custom aptamer development.
Aptamer Handling & Storage
Specific buffers and re-folding procedures are recommended for optimal aptamer stability and performance. Download the Aptamer Best Practices: Handling & Storage Guide to learn more.
Catalog Aptamer Information
MRSA Aptamer ATW0033 Information